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Received 4 September 2010; received in revised form 27 October 2010; accepted 2 November 2010; Available online 16 December 2010AbstractObjective: Diabetic patients often present with diffuse coronary disease than nondiabetic patients posing a greater surgical challenge during
off-pump revascularization. In this study, the safety, feasibility, and completeness of revascularization for this subset of patients was assessed.
Methods: From 2002 to 2008, 1015 diabetic patients underwent myocardial revascularization. Patients received either off-pump coronary artery
bypass (OPCAB; n = 540; 53%) or coronary artery bypass grafting (CABG; n = 475; 47%). Data collection was performed prospectively and data
analysis was done by propensity-score (PS)-adjusted regression analysis. Primary endpoints were mortality, major adverse cardiac and
cerebrovascular events (MACCEs), and a composite endpoint including major noncardiac adverse events (MNCAEs) such as respiratory failure,
renal failure, and rethoracotomy for bleeding was applied. An index of complete revascularization (ICOR) was defined to assess complete
revascularization by dividing the total number of distal anastomoses by the number of diseased vessels. Complete revascularization was assumed
when ICOR was>1. Results: OPCAB patients had a significantly lower mortality-rate (1.1% vs 3.8%; propensity-adjusted odds ratio (PAOR) = 0.11;
p = 0.018) and displayed less frequent MACCE (8.3% vs 17.9%; PAOR = 0.66; p = 0.07) including myocardial infarction (1.3% vs 3.2%; PAOR = 0.33;
p = 0.06) and stroke (0.7% vs 2.3%; PAOR = 0.28; p = 0.13). Similarly, a significantly lower occurrence of the noncardiac composite endpoint
(MNCAE) (PAOR = 0.46; confidence interval (CI) 95% 0.35—0.91; p < 0.001) was detected. In particular, lesser respiratory failure (0.9% vs 4.3%;
PAOR = 0.24; p = 0.63) and pleural effusions (3.3% vs 7.5%; PAOR = 0.45; p = 0.04) occurred, so that fast extubation (12 h postoperative) was
more frequently possible (58.3% vs 34.2%; PAOR = 1.64; p = 0.007). The number of arterial grafts was significantly higher among OPCAB patients
(1.54  0.89 vs 1.33  0.81; p = 0.006) due to a more frequent use of the right-internal mammary artery (35.6% vs 22.9%; p < 0.001). ICOR was
significantly higher among CABG patients (1.24  0.34 vs 1.30  0.28; p = 0.001). However, for similar proportions in both groups, an ICOR > 1was
achieved clearly indicating complete revascularization (94.3% vs 93.7%; p = 0.24). Conclusions: OPCAB offers a lower mortality and superior
postoperative outcomes in diabetic patients withmultivessel disease. Arterial grafts are usedmore frequently thatmay contribute to better long-
term outcomes and the OPCAB approach does not come at the cost of less complete revascularization.
# 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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Diabetes mellitus (DM) is a well-known risk factor for the
development of coronary artery disease (CAD) [1]. Affected
patients often present with advanced and more diffuse
disease, involving multiple vessels and rapidly progressive
CAD when compared to nondiabetic patients [2]. Therefore
DM is a well-established predictor for adverse outcome of
both surgical as well as percutaneous revascularization [3].§ Presented at the 24th Annual Meeting of the European Association for
Cardio-thoracic Surgery, Geneva, Switzerland, September 11—15, 2010.
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doi:10.1016/j.ejcts.2010.11.003Particularly percutaneous coronary interventions (PCIs),
including angioplasty and stent placement, have been
reported to carry a higher risk for re-stenosis and recurrent
symptoms. This has been confirmed by various randomized
trials, suggesting that coronary artery bypass grafting (CABG)
is the most appropriate therapy (according to the guidelines
of the American College of Cardiology/American Heart
Association) for diabetic patients with multivessel disease
(MVD) than PCI [4—6].
Conventional CABG is performed with cardio-pulmonary
bypass (CBP), which is associated with serious complications
such as stroke [7], renal dysfunction, and systemic inflam-
matory response syndrome (SIRS) [8]. Off-pump coronary
artery bypass (OPCAB) surgery has been demonstrated to
have a comparable risk-adjusted mortality and to be
associated with less major complications [9,10]. CurrentSurgery. Published by Elsevier B.V. All rights reserved.
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Table 2. Risk factors and co-morbidities.
Parameter OPCAB
(n = 540)
CABG
(n = 475)
p-Value
Hypercholesterinemia (%) 70.7 74.9 0.21
Hypertension (%) 58.5 75.4 <0.0001
Positive family history (%) 30.7 29.9 0.78
Smoking (%) 48.5 49.7 0.74
Adipositas (%) 58.7 52.0 0.037
PAD (%) 21.0 14.1 0.005
COPD (%) 7.2 7.4 1.00
Acute myocardial infarction
(<90 days) (%)
17.2 21.3 0.11
Previous MI (>90 days) (%) 40.0 44.0 0.2
Preoperative cardiogenic
shock (%)
1.7 1.5 1.00
Previous cardiogenic shock
(>90 days) (%)
10.0 5.1 0.013
Cerebrovascular disease (%) 2.0 1.3 0.47
Previous syncope (%) 1.7 2.1 0.79
Renal disease (%) 5.7 3.6 0.2
Instable angina (%) 11.7 20.6 0.001
IABP preoperative (%) 11.5 23.1 0.001
PAD: peripheral artery disease, COPD: chronic obstructive pulmonary disease,
MI: myocardial infarction, IABP: intra-aortic balloon pump.data suggest that OPCAB may be superior for high-risk
patients [11]. However, for diabetic patients with MVD only
limited data are available [12,13].
In this study, we compare OPCAB to conventional CABG for
diabetic patients with MVD with regard to mortality, post-
operative morbidity, and completeness of revascularization.
2. Material and methods
From 2002 to 2008, 1015 diabetic patients with MVD
underwent myocardial revascularization at our institution.
Patients received either OPCAB (n = 540; 53%; group A) or
CABG (n = 475; 47%; group B). Data collection was performed
prospectively and was approved by our local institutional
review board (IRB), including a waiver of informed consent.
Surgery was performed as follows: elective (68.7% vs 64.4%;
p = 0.16), urgent (24.6% vs 30.9%; p = 0.029), and emergent
(6.7% vs 4.6%; p = 0.18), respectively. Mean preoperative risk
stratification was performed by use of the European System
for Cardiac Operative Risk Evaluation (Euroscore).
Tables 1 and 2 summarize demographics and preoperative
variables for both the groups. In brief, OPCAB patients and
CABG patients were well comparable with regard to mean
EuroScore (3.9  1.2 vs 4.1  1.1), age, and gender distribu-
tion. OPCAB patients presented more significantly with left
main disease (31.1% vs 23.8%; p = 0.009), whereas patients
undergoing CABG more frequently suffered from triple vessel
disease (76.7% vs 88.4%; p = 0.001) and presented more
frequently for redo surgery (2.8% vs 9.1%; p = 0.001).
OPCAB patients appeared to suffer more significantly from
peripheral artery disease (PAD) (21.0% vs 14.1%; p = 0.005)
and had a more frequent history of previous cardiogenic
shock (>90 days) (10.0% vs 5.1%; p = 0.013). By contrast,Table 1. Preoperative characteristics and demographics.
Parameter OPCAB (n = 540) CABG (n = 475) p-Value
Age (years) 65  10 64  9 0.18
Male (%) 73 77 0.08
Female (%) 27 23 0.08
EuroScore 3.9  1.2 4.1  1.1 0.01
EF (%) 55  14 56  14 0.12
BMI (kg/m2) 28  4 28  4 1.00
Elective (%) 68.7 64.4 0.16
Urgent (%) 24.6 30.9 0.029
Emergent (%) 6.7 4.6 0.18
Sinus rhythm (%) 97.3 96.2 0.54
Atrial fibrillation (%) 2.0 2.9 0.49
Pacemaker (%) 0.7 0.8 1.00
No of diseased vessels 2.75  0.47 2.95  0.25 0.001
1-vessel disease (%) 1.9 1.9 1.00
2-vessel disease (%) 21.5 9.7 0.001
3-vessel disease (%) 76.7 88.4 0.001
Left main disease (%) 31.1 23.8 0.009
CCS 1 (%) 5.4 5.7 0.89
CCS 2 (%) 34.7 29.3 0.09
CCS 3 (%) 45.6 46.9 0.69
CCS 4 (%) 14.3 18.1 0.13
NYHA 1 (%) 57.1 73.3 <0.0001
NYHA 2 (%) 28.6 16.2 <0.0001
NYHA 3 (%) 12.9 8.4 0.029
NYHA 4 (%) 1.4 2.1 0.47
Redo surgery (%) 2.8 9.1 0.001
EF: ejection fraction, BMI: body mass index, CCS: Canadian Cardiovascular
Society Angina Classification, NYHA: New York Heart Association. All values
which are significant ( p < 0.05) are bold.CABG patients presented with higher instable angina (11.7%
vs 20.6%; p = 0.001) requiring preoperative implantation of
an intra-aortic balloon pump (IABP; 11.5% vs 23.1%;
p = 0.0001).
2.1. Surgical technique
CABG was performed using standard CBP techniques and
proximal anastomosis was done with complete clamping of
the aorta. OPCAB procedures were performed as previously
described [14]. In brief, heparin was administered to obtain
active clotting time (ACT) in excess of 350 s and repeated if
necessary. Epicardial temporary pacemaker wires were
placed, before a stabilizer (OctopusW4 Tissue Stabilizer,
Medtronic, Minneapolis, USA) was used to expose the target
vessel. A shunt (ClearViewW Intracoronary Shunt, Medtronic,
Minneapolis, USA) was routinely inserted and a mister blower
(Guidant, Indianapolis, USA) with CO2 and water was used to
clear the surgical field. If no T-graft was performed, proximal
anastomosis was carried out in a clampless fashion (‘no
touch’ technique for proximal anastomosis) using the heart-
string device (HeartstringTM Proximal Seal System, Guidant,
Indianapolis, USA). Routine ultrasound flow measurement
(MediStim QuickFitW) was done in all cases. The strategy for
the perioperative glycemic control was based on the Portland
scheme described by Furnary et al. [15].
2.2. Strategy for revascularization
Surgical revascularization was mainly started by left
internal mammary artery (LIMA) to left anterior descending
(LAD) grafting. Following this, the right coronary system was
approached, and finally the circumflex territory was
revascularized. In patients with left main disease, LAD and
circumflex arteries were always grafted, regardless of the
degree of stenosis. All other vessels with significant lesions
(>70%) were identified preoperatively in the angiogram and
selected as target for revascularization.
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Endpoints analyzed are mortality and major adverse
cardiac events (MACCEs) including death, myocardial infarc-
tion, recurrent angina, and stroke. A composite endpoint
including major noncardiac adverse events (MNCAEs) such as
respiratory failure, renal failure, and rethoracotomy for
bleeding was created. For converted patients, the ‘inten-
tion-to-treat’ methodology was applied.
An index of complete revascularization (ICOR) was
calculated for each patient. The CRI was defined as the
total number of distal grafts divided by the number of the
affected coronary vessels reported on the preoperative
coronary angiogram. Complete revascularization (CR) was
assumed when the number of distal anastomoses was larger
than that of diseased vessels [9].
Continuous data are presented as mean  standard
deviation and are compared using the Mann—Whitney test.
Categorical data are presented as number and percentage
and are compared using the Chi-square test or Fisher’s exact
test, where appropriate. Odds ratios with 95% confidence
intervals are computed using univariate logistic regression.
A propensity score (PS) was computed using logistic
regression with 52 preoperative variables to balance
characteristics between OPCAB and on-pump groups (c-
statistic 0.87). In this computation, missing values in
preoperative variables were replaced using regression
methods. The PS then was divided into quintiles and
analyzed as a categorical variable. PS-adjusted logistic
regression analysis was performed to assess binary endpoints
and two-way analysis of variance for continuous endpoints.
All analyses were performed using SPSS 18 (SPSS Inc.,
Chicago, IL). P-values < 0.05 are assumed to be statistically
significant.Table 3. Crude outcome data.
Parameter OPCAB
(n = 540)
CABG
(n = 4
Mortality (%) 1.1 3.8
Neurological events (central) (%) 0.7 2.3
Neurological events (peripheral) (%) 0.7 0.6
Re-thoracotomy for bleeding (%) 3.9 6.7
Myocardial infarction (%) 1.3 3.2
Low cardiac output (%) 1.4 4.1
Graft occlusion (%) 1.4 2.1
Cardiac tamponade (%) 0.5 0.2
Arrythmia (%) 0.9 2.1
IABP postop (%) 0.2 2.5
Renal dysfunction (%) 4.1 6.3
Dialysis (%) 3.3 3.2
No ventilation (%) 2.8 1.7
Ventilation <12 h (%) 58.3 34.2
Ventilation > 12 h (%) 31.9 49.8
Prolonged ventilation > 24 h (%) 7.3 14.3
Respiratory failure (%) 0.9 4.3
Pleural effusions/pneumothorax (%) 3.3 7.5
Sinus rhythm (%) 94.3 94.7
Atrial fibrillation (%) 4.3 4.2
Need for pacemaker (%) 2.0 1.1
MACCE (%) 8.3 17.9
MNCAE (%) 9.4 18.5
MACE: major adverse cardiac events, MNACE: major noncardiac adverse events.3. Results
3.1. Crude outcome data (Table 3)
OPCAB patients had a significantly lower mortality rate
than CABG patients (1.1% vs 3.8%; odds ratio (OR) = 0.28;
confidence interval (CI) 95% 0.11—0.72; p = 0.008) and
suffered from significantly less major adverse cardiac
events (MACCEs) (8.3% vs 17.9%; OR = 0.41; CI 95% 0.28—
0.61; p < 0.001) and major noncardiac adverse events
(MNCAE) (9.4% vs 18.5%; OR = 0.46; CI 95% 0.31—0.66;
p < 0.001). In detail, OPCAB patients displayed a signifi-
cant benefit with regard to stroke (0.7% vs 2.3%; OR = 0.31;
CI 95% 0.10—0.99; p = 0.043), reoperation for bleeding
(3.9% vs 6.7%; OR = 0.56; CI 95% 0.31—0.98; p = 0.044),
need for postoperative IABP implantation (0.2% vs 2.5%;
OR = 0.07; CI 95% 0.01—0.55; p = 0.011), as well as the
occurrence of respiratory failure (0.9% vs 4.3%; OR = 0.21;
CI 95% 0.05—0.91; p = 0.038). This was clearly reflected by
the lower frequency of prolonged ventilation (7.3% vs
14.3%; OR = 0.46; CI 95% 0.29—0.73; p = 0.01), the lower
rate of pleural effusions and/or pneumothorax (3.3% vs
7.5%; OR = 0.42; CI 95% 0.20—0.87; p = 0.02), as well as the
overall shorter time to extubation (<12 h) (58.3% vs 34.2%;
OR = 2.69; CI 95% 2.00—3.51; p < 0.001) clearly indicating
a more straightforward postoperative course. Similarly,
the frequency of myocardial infarction (1.3% vs 3.2%;
OR = 0.41; CI 95% 0.13—1.26; p = 0.12), graft occlusion
(1.4% vs 2.1%; OR = 0.65; CI 95% 0.17—2.40; p = 0.52),
low cardiac output (1.4% vs 4.1%; OR = 0.33; CI 95% 0.09—
1.15; p = 0.08), and renal failure (4.1% vs 6.3%; OR = 0.63;
CI 95% 0.35—1.10; p = 0.63) was lower in
the OPCAB group, but failed to achieve statistical
significance.75)
OR CI 95% p-Value
0.28 0.11—0.72 0.008
0.31 0.10—0.99 0.043
1.17 0.26—5.27 0.83
0.56 0.31—0.98 0.044
0.41 0.13—1.26 0.12
0.33 0.09—1.15 0.08
0.65 0.17—2.40 0.52
2.20 0.13—35.39 0.57
0.43 0.09—1.99 0.28
0.07 0.01—0.55 0.011
0.63 0.35—1.10 0.10
1.00 0.46—2.38 0.99
1.66 0.67—4.10 0.27
2.69 2.00—3.51 <0.001
0.47 0.36—0.62 <0.001
0.46 0.29—0.73 0.01
0.21 0.05—0.91 0.038
0.42 0.20—0.87 0.02
0.92 0.49—1.74 0.80
1.00 0.50—2.10 0.93
1.91 0.58—6.34 0.28
0.41 0.28—0.61 <0.001
0.46 0.31—0.66 <0.001
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Table 4. Propensity adjusted outcome data.
Parameter OR CI 95% p-Value
Mortality (%) 0.11 0.01—0.68 0.018
Neurological events (central) (%) 0.28 0.05—1.42 0.12
Neurological events (peripheral) (%) 0.10 0.01—4.80 0.24
Re-thoracotomy for bleeding (%) 0.58 0.28—1.23 0.16
Myocardial Infarction (%) 0.33 0.10—1.07 0.06
Low cardiac output (%) 0.34 0.09—1.24 0.10
Graft occlusion (%) 0.39 0.09—1.59 0.18
Cardiac tamponade (%) 1.35 0.61—29.66 0.85
Arrythmia (%) 0.97 0.19—4.85 0.97
IABP postop (%) 0.15 0.02—1.27 0.08
Renal dysfunction (%) 0.57 0.25—1.27 0.17
Dialysis (%) 0.85 0.32—2.19 0.73
No ventilation (%) 2.32 0.65—8.34 0.20
Ventilation <12 h (%) 1.64 1.14—2.36 0.007
Ventilation > 12 h (%) 0.71 0.49—1.02 0.06
Prolonged ventilation > 24 h (%) 0.59 0.32—1.07 0.86
Respiratory failure (%) 0.23 0.05—1.07 0.06
Pleural effusions/pneumothorax (%) 0.45 0.21—0.96 0.04
Sinus rhythm (%) 0.59 0.28—1.24 0.17
Atrial fibrillation (%) 1.75 0.77—3.98 0.18
Need for pacemaker (%) 1.68 0.35—8.14 0.51
MACCE (%) 0.66 0.42—1.04 0.07
MNCAE (%) 0.57 0.35—0.91 0.02
MACE: major adverse cardiac events, MNACE: major noncardiac adverse
events.3.2. Propensity-adjusted outcome data (Table 4)
After PS adjustment, OPCAB patients still displayed a
significantly lower mortality rate (propensity-adjusted odds
ratio (PAOR) = 0.11; CI 95% 0.01—0.68; p = 0.018) as well as a
significantly lower occurrence of the noncardiac composite
endpoint (MNCAE) (PAOR = 0.46; CI 95% 0.35—0.91;
p < 0.001). Next, still significantly more OPCAB was extu-
bated within the first 12 h (PAOR = 1.64; CI 95% 1.14—2.36;
p = 0.007) and presented with less pleural effusions or
pneumothorax (PAOR = 0.45; CI 95% 0.21—0.96; p = 0.04)
reflecting a faster postoperative course.
With regard to MACCE (PAOR = 0.66; CI 95% 0.42—1.04;
p = 0.07) and major single complications such as stroke
(PAOR = 0.28; CI 95% 0.05—1.42; p = 0.12), reoperation for
bleeding (PAOR = 0.58; CI 95% 0.28—1.23; p = 0.16), post-
operative IABP implantation (PAOR = 0.15; CI 95% 0.02—1.27;
p = 0.08), and respiratory failure (PAOR = 0.23; CI 95% 0.05—
1.07; p = 0.06), the protective benefit of OPCAB remained
detectable, but failed to achieve statistical significance after
PS adjustment.
3.3. Intra-operative data and completeness of
revascularization (Table 5)
The need for intra-operative implantation of an IABP was
similar in both groups (3.5% vs 6.1%; p = 0.80) and conversion
to CPB became necessary in 5.6% of all OPCAB patients. If
converted, the operation was continued in a beating-heart
fashion.
OPCAB patients presented with a lower mean number of
the diseased coronary vessels (2.75  0.47 vs 2.95  0.25;
p = 0.001) and also received a lower number of total distal
grafts (3.37  0.99 vs 3.83  0.95; p < 0.001). In detail, the
number of arterial grafts was significantly higher among
these patients (1.54  0.88 vs 1.33  0.81; p = 0.006)
following the more frequent use of the right internal
mammary artery (RIMA) (35.6% vs 22.9%; p < 0.001) and
the radial artery (13.5% vs 5.5%; p = 0.001). Furthermore, in
OPCAB patients, significantly less proximal anastomoses
(1.11  0.59 vs 1.51  0.63; p < 0.001) were performed andTable 5. Intra-operative data.
Parameter OPCAB
(n = 540)
CPB conversion (%) 5.6
CPB time (min) —
Aortic X-clamp time (min) —
Arterial grafts per patient 1.54  0.88
LIMA (%) 94.6
RIMA (%) 35.6
Radial artery (%) 13.5
SVG per patient 1.83  1.24
Use of SVG (%) 78.7
Total number of proximal anastomoses 1.11  0.59
No proximal anastomosis/T-Graft (%) 9.4
Total number of grafts per patient 3.37  0.99
Number of diseased vessels 2.75  0.47
Completeness of revascularization (%) 94.3
Index of complete revascularization (ICOR) 1.24  0.34
IABP intra-operative (%) 3.5
CPB: cardio-pulmonary bypass, LIMA: left internal mammary artery, RIMA: right internin 9.3% of these patients revascularization was done without
necessity of any proximal anastomosis (9.4% vs 6.7%;
p = 0.013). By contrast, OPCAB patients received less
saphenous vein grafts (SVGs) when compared to the on-
CABG group (78.7% vs 90.7%; p < 0.001).
The ICOR appeared to be significantly higher among CABG
patients (1.24  0.34 vs 1.30  0.28; p = 0.001). However,
for similar proportions in both the groups (94.3% vs 93.7%;
p = 0.24), a CRI > 1 was achieved clearly indicating CR.
4. Discussion
OPCAB is a safe and feasible option for diabetic patients
with MVD. The data presented here show a significant benefit
with regard to mortality, MNCAEs, and the time to extubationCABG
(n = 475)
p-Value
— —
109  40 —
53  28 —
1.33  0.81 0.006
92.8 0.68
22.9 <0.001
5.5 0.001
2.50  1.15 <0.001
90.7 <0.001
1.51  0.63 <0.001
6.7 0.013
3.83  0.85 <0.001
2.95  0.25 0.001
93.7 0.24
1.30  0.28 0.001
6.1 0.80
al mammary artery, SVG: saphenous vein graft, IABP: intra-aortic balloon pump.
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major complications such as stroke, rethoracotomy for
bleeding, and postoperative IABP implantation, confirming
the overall beneficial effect of OPCAB in this subset of
patients.
Although various reports have suggested OPCAB to be
superior for high-risk patients [11,16], only a few reports
comparing OPCAB versus CABG in diabetic patients with MVD
are available [12,13]. Magee et al. compared 2891 patients
with diabetes, who underwent either OPCAB (n = 346) or
classical on-pump surgery (n = 2545). Even though the
authors did not find a survival advantage, they found OPCAB
to be associated with a significantly decreased incidence of
postoperative complications including prolonged ventila-
tion and renal failure requiring dialysis [12]. Srinivasan et al.
also recently analyzed 951 consecutive diabetic patients
who underwent isolated CABG. Of these patients, 186
(19.6%) had off-pump coronary procedures. After risk
adjusting with propensity scoring, off-pump patients had
a significantly lower incidence of stroke and renal failure,
whereas no in-hospital survival difference could be demon-
strated [13]. Taken together, these reports indicate a benefit
for diabetic patientswith regard to postoperativemorbidity,
which is generally in line with our findings. In the context of
the previous results, it is to mention that the study of Magee
et al. involved 22 surgeons of various institutions with
different selection criteria and a PS adjustment was not
performed. The report of Srinivasan, although similar
in size, showed a certain imbalance of patient group
distribution.
CPB has been demonstrated to be an independent risk
factor for neurological events [7]. Various studies have
proven embolic showers during cannulation, clamping or de-
clamping maneuvers and especially with the release of the
aortic cross-clamp [17]. Therefore, recent data proposed the
protective effect of OPCAB despite requiring side bite
clamping of the aorta for performing proximal anastomosis
[18]. Thus, we avoided further reducing the risk of
neurological events to 0.7% in the OPCAB patients by
applying no-touch technique using the Heartstring (Guidant,
Indianapolis, USA) device. The occurrence of stroke can be
minimized with this technique; it is particularly helpful in
patients presenting with a rapidly progressive CAD or
advanced atherosclerosis [7] and yields similar results as
with all arterial grafting using no-touch technique.
When comparing these results to studies in which patients
underwent total arterial grafting strategies, that is, using
bilateral internal thoracic arteries and T-grafts [19], our data
demonstrate that our applied no-touch technique could
minimize neurological complications to the level of the
current gold standard, that is, the ‘total arterial grafting
technique’.
This is an important message, particularly when taking
various randomized trials into account comparing the
outcomes of PCI and CABG in diabetic patients with MVD.
Recent studies [5,20,21] including the SYNTAX trial [5] and
the ARTS-II tria [20] reported a higher incidence of stroke in
the CABG group and created a major concern for surgical
revascularization. The low stroke rate associated with a
standardized OPCAB no-touch strategy can potentially
minimize this problem. This finding is supported by a recenttrial of Briguori et al. who did not detect a higher incidence
for stroke when comparing outcomes after drug-eluting stent
(DES) implantation versus OPCAB in patients with type 2 DM
and MVD [4].
However, even with a technique in a standardized fashion,
the risk of intra-operative stroke cannot be completely
eliminated. This also applies to all arterial grafting [19] as
well as interventional approaches [4—6,20] and is most
probably linked to the underlying risk profile defined by the
general health condition of a patient [22].
The standardized OPCAB approach comes not at the cost
of less CR. This is an important finding, since CR has been
reported to be a crucial predictor for the long-term
outcome [9,10] and is one of the main arguments
commonly used against OPCAB [23,24]. In this study, CR
was achieved in similar levels for both the groups what is in
line with the recent data of Puskas et al. who demon-
strated feasibility of complete revascularization in
OPCAB [10].
5. Limitations
Due to its retrospective nature and nonrandomized
design, all established disadvantages apply. PSs are valuable
and helpful tools, but the allocation of a patient to either off-
or on-pump surgery is based on criteria that may be buried at
the time of the decision and then impossible to be
retrospectively recovered. Therefore, even after careful
application of PSs, distinguishing between surgeon and
treatment differences remains difficult. Although balancing
scores constitute the most rigorous methods available for
apples-to-apples investigation of causal effects on outcome
in the retrospective, nonrandomized setting, they are not
equal to randomized clinical trials and they cannot account
for unknown variables affecting outcome that are not
correlated strongly withmeasured variables [25]. In addition,
our results lack the force of numbers and certainly a higher
level of significance may have been achieved, had we had a
larger patient cohort to analyze. Although the EuroScore and
the total number of diseased vessels were included in the
propensity adjustment, a certain bias may apply, since
OPCAB patients had a significantly lower EuroScore and had
less MVD. Finally, the study period was quite long with most
CABG patients being from the early part of the study, whereas
the major part of OPCAB patients was from the later part of
the study period.
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Appendix A. Conference discussion
Mr G. Cooper (Sheffield, United Kingdom): I’d just like to ask you a little
bit about the methodology, because, as you rightly pointed out in your last
slide, in a cohort study such as this, a difference in outcome can be due to
selection bias rather than to the treatment modality. And I wonder if you could
just expand a bit on your method of selecting patients for off- or on-pump
surgery.
Dr Emmert: Of course, this was basically explained by the time we
performed this surgery. We introduced OPCAB in Zurich about 8 years ago, and
it was fully established in 2004. By then certainly, the numbers of OPCAB
increased and the numbers of on-pump decreased. Now we are performing and
we are planning (and this is very important) almost every patient in the OPCAB
fashion. So this was actually the methodology.
Mr Cooper: So if my understanding is correct, most of the on-pump surgery
was done before 2004 and the off-pump surgery was done from 2004 onwards?
Dr Emmert: Not at all. Because, as I mentioned, we introduced it in 2004
and then we increased year by year, of course.
Dr Cooper: But the selection is then by time?
Dr Emmert: By time, yes.
Dr Cooper: In the UK, between 2001 and 2008, we saw a 25% reduction in
mortality for coronary bypass surgery over that period. Do you think your
results could be explained by a similar trend in mortality reduction in
Switzerland?
Dr Emmert: Actually, that’s a good question, and you see that I’m still very
young, but I try to comment. What I found when I queried our database was
that the off-pump cases increased by time. In this study, I’m just presenting
1000 patients; however, I evaluated over 6000 patients and indeed detected
similar trends to less mortality as you just mentioned.
Dr D. Taggart (Oxford, United Kingdom): If you look at your two groups of
patients, you see that there was a far higher use of bilateral IMAs in the off-
pump group. Now you could argue that people doing off-pump surgery may be
technically better? Certainly the use of internal mammary arteries again
requires a different degree of technical expertise. So do you not think that,
perhaps, the real difference in mortality that you saw in these patients was
that you had two groups of surgeons with different operating skills?
Dr Emmert: That’s correct. I agree with you because, of course, we all
know the better outcomewhen performing total arterial grafting. On the other
hand, here in Zurich all surgeons perform OPCAB and are experienced with this
technique. However, this is a retrospective study with all the disadvantages
that apply and I don’t want to claim anything. Zurich is a very experienced
OPCAB center now, we can just show our data and try to give an idea to all the
surgeons attending this Congress about the clinical routine. So you’re certainly
right that there may be a selection bias, and the best trial would be, as shown
by the ROOBY trial, a prospective trial, but otherwise I also think we can
provide a high number of patients in our experience and this might be of help
for the audience.
Dr J. Ennker (Lahr, Germany): Our experience in OPCAB dates back to
September 1997, and my question to you is: Why are you using the Heartstring
procedure so often? Because it has been proven and shown in the literature
that you can put a vein graft into the LIMA and you can do Y grafting, so there is
only very rarely an indication to place a proximal anastomosis. I can’t see your
point for that.
Dr Emmert: That’s a good question. As I mentioned, for technical aspects I
would refer this question to one of my coauthors in the audience to comment.
Dr Salzberg: In regard to the usage of Heartstring versus composite graft,
we tend to do composite grafts in arterials, so we’re using twomammaries, but
no veno-arterial composite grafts. And therefore, vein grafts or radials are
implanted into the aorta with the Heartstring.
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0.9% for all-comers with a proximal anastomosis. I think it’s 1.9% compared to
partial clamping and over 3% for on-pump. So there is a significant decrease
there. And we’re going to publish 1500 proximal anastomoses.
Dr Ennker: That’s very fine, but it’s unnecessary. It has been shown by
Calafiore in thousands of cases and in my own experience since 1997. But this is
your way.
Dr S. Attaran (Liverpool, United Kingdom): I have two questions for you.
Firstly, what patient characteristics did you use to match the groups?
Clearly, they are very different. But did you go for EuroSCORE or any other
preoperative modality?
And my second question is that with your findings, has it actually changed
your practice, or are you planning to do your diabetic patients all off-pump
from now on?Dr Emmert: First, of course, I took advice from a specialist in statistics and
in this study we introduced 52 variables for the preoperative adjustment, as
for example, cardiovascular risk profiles, emergent or urgent or elective cases,
prior myocardial infarction, the number of diseased vessels and others. So we
tried to do our best to eliminate the disadvantages of a retrospective design we
clearly know about.
Your second question is a very good question. When I joined this clinic in
2008, the OPCAB strategy was fully in place. However, there might be one
aspect to be addressed. Some surgeons still perform partial clamping for
the proximal anastomosis. And in presenting my results, I have tried to
highlight that whenever the aorta is clamped, whether partial or even
cross-clamped, there is no difference in reduction for stroke. And that’s
why I think when a proximal anastomosis is needed, the Heartstring device
might be helpful.
